Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technolo... More >>

Recent NewsMore >>
03/04/15LabCorp Contributes to Clinical Research Collaborations Directed at Advancing Treatment of Breast Cancer and Viral Hepatitis
Studies Promote Personalized Medicine and Advance Public Health Initiatives BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 4, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today highlighted clinical research efforts in oncology and viral hepatitis that demonstrate its commitment to novel diagnostic capabilities and unique bioinformatics resources to enhance patient care in today’s rapidly evolving healthcare system. ... 
Printer Friendly Version
03/03/15LabCorp is Scheduled to Present at the Barclays Capital 2015 Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 3, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Barclays Capital 2015 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 10, 2015 at 8:30 AM (Eastern Time). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay. ... 
Printer Friendly Version
02/20/15Laboratory Corporation of America® Holdings Announces 2014 Fourth Quarter and Full Year Results and Provides 2015 Guidance
Strong Q4 volume drives sales of $1.5 billion Diluted Q4 EPS of $1.39; Adjusted Q4 EPS of $1.65 Q4 Operating Cash Flow of approximately $214 million Q4 Free Cash Flow of approximately $167 million Announces Project LaunchPad, its enterprise-wide business process improvement initiative 2015 Adjusted EPS guidance of $7.35 - $7.70, inclusive of Covance as of... 
Printer Friendly Version
02/19/15LabCorp Completes Acquisition of Covance
Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 19, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the completion of its acquisition of Covance Inc., following its entry into a definitive purchase agreement on November 2, 2014. At closing, the purchase consideration was valued at ... 
Printer Friendly Version
Upcoming EventsMore >>
Laboratory Corporation of America Holdings at Barclays Capital 2015 Global Healthcare Conference
LH (Common)
Change Stock is Up 0.04
Intraday High$125.09
Intraday Low$122.86
Data as of 03/04/15
4:01 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release